EDNRA and cancer: Therefore, ETA expression is closely related to the survival rates of patients with several types of cancers10–12, and endothelin receptor antagonists, including zibotentan, atrasentan, bosentan, macitentan, and ambrisentan, have been developed as drugs for treating cancer by inhibiting downstream ETA signaling13.